Biohaven Pharma (BHVN) Tops Q4 EPS by 28c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/4/2026
- AI-linked earnings, Mideast deal hopes send Dow, S&P 500 to record highs
- Caterpillar stock jumps on strong earnings and revenue beat
- Optical component stocks rally on proposed U.S. ban on Chinese tech
- BofA says this memory stock could double. Here are 5 reasons why
- Merck shares rise on big Q2 earnings beat, adjusted FY outlook
- Nutanix to cut 5% of workforce, expects up to $43M in charges
- Palantir posts 93% revenue growth in Q2 2026, raises full-year outlook
- Grainger CFO resigns, interim replacement named
- Microsoft joins, Broadcom exits Goldman's top-stocks list
- Walmart dips after Oppenheimer downgrades shares on difficult short-term setup
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
March 1, 2021 7:30 AM ESTNEW HAVEN, Conn., March 1, 2021 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. ("Biohaven" or the "Company") (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders, today reported financial results for the fourth quarter and full year 2020 and provided a review of recent accomplishments and anticipated upcoming milestones.
